Sjogrens Syndrome Market Size, Share, Growth, Trends, and Global Industry Analysis: By Drug (Pilocarpine, Cyclosporine, NSAIDS, Hydroxychlroquine) By Type (Primary Sjogrens Syndrome, Secondary Sjogrens Syndrome) By End-User (Hospitals, Clinics, Pharmacies, Online Pharmacies) and Region Forecast 2020-20301

Sjogren’s Syndrome Market size was valued at US$ 352.1 million in 2024 and is expected to reach US$ 519.0 million by 2031, growing at a significant CAGR of 5.7% from 2025-2031. Sjogren's syndrome is an autoimmune condition that develops when the body’s immune system attacks the gland that produces moisture in the mouth, eyes, and other body parts resulting in dryness of the eyes and mouth due to inflammation and resultant pathology of the lacrimal and salivary glands. Up to 50% of those who are affected also experience extra-glandular involvement in other organs, including the joints, skin, lungs, GI tract, neurological system, and kidneys.

According to WHO, approximately 1% of the U.S. population is affected by Sjogren’s with 9 out of 10 patients being women. The treatment regimen generally includes local therapies like pilocarpine, and cevimeline and, systemic therapies like corticosteroids, hydroxychloroquine, and immunosuppressants. The increase in incidence of Sjogren’s syndrome, increased awareness of preventive attention and increased income among the population is currently driving the market.

The recent studies focussing on alternative strategies in molecular technology have produced a wide range of novel putative blood, salivary, and histologic biomarkers, increasing the opportunities for market development. The development of a robust drug pipeline during COVID-19 has presented huge opportunities for the development of several NSAIDs and hydroxychloroquine and is expected to have a significant impact on the Sjogren’s syndrome market. For instance, in January 2023, Horizon announced that Dazodalibep had achieved approval in 2^nd phase and is currently undergoing 3^rd phase. Based on key molecule type, the biologics segment is dominating the market owing to the extensive use of B-cell targeted therapies, therapies targeting various cytokines, chemokines, and Toll-like receptors.  

However according to research conducted currently, no permanent cure is available, treatments only treat the symptoms or are viewed as ineffective by many patients. Moreover, tight government regulations, expensive treatment costs, and Sjogren's disease consequences including acute dehydration, considerable weight loss, and inflammation, slows down the market's expansion. However, a rise in awareness of preventive attention, an increase in disposable income among the population, developed infrastructure, and increased pharmaceutical and biotechnology industries have a significant positive effect on the market and are expected to burgeon in the forecast period.

Key Developments

• In February 2022, Dompe announced the first patient enrolment in the Phase 3 trial of cenegermin in patients with severe Sjogren’s-related dry eye disease.
• In March 2019, Wize Pharma, Inc., a clinical-stage biopharmaceutical company focused on ophthalmic disorders announced LO2A Licensor, Resdevco, was granted market approval for the treatment of Sjögren's Syndrome in Hungary